TEL AVIV, Israel, Dec. 18, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™
Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced the
publication of a meta-analysis of four clinical studies involving dual layered and mesh-covered stents in the December 10, 2018
issue of JACC: Cardiovascular Interventions. The analysis concluded that carotid artery disease (CAD) patients treated
with mesh-covered stents experienced a 30-day minor stroke rate of 1.25%, lower than 30-day minor stroke rates reported in other
widely cited studies, such as CREST and ACT 1, for patients treated with both carotid endarterectomy (CEA) and with those treated
with conventional carotid stents. Moreover, CREST and ACT 1 involved lower-risk patient populations as compared to the four studies
included in the meta-analysis, which included a higher percentage of high-risk and elderly patients.
“The compelling results of this independent and comprehensive meta-analysis, which includes four studies of
high-risk patients treated for carotid artery disease, add to the growing body of evidence that points to superior clinical
outcomes with next generation mesh-covered or dual layered devices versus their conventional carotid stent counterparts,” said
James Barry, PhD, Chief Executive Officer of InspireMD. “As we continue to expand the commercial availability of our
MicroNet™-covered product, CGuard™ EPS, including the submission of a U.S. IDE expected in mid-2019, we welcome additional analyses
such as these that further support the positive findings from our own studies with MicroNet-covered products.”
This paper is also the focus of a follow-up article, dated December 12, 2018, that appeared in the
publication Medcape along with a discussion with a leading European interventional cardiologist, Professor Harald Mudra,
MD, Städtisches Klinikum, Munich, Germany, who commented, “I think we are seeing a new milestone with these mesh-covered stents in
that we can achieve a very acceptable, low rate of complications and stroke even in high-risk patients. If confirmed in larger and
longer trials, these stents could open up a new population for carotid stenting who have previously been thought of as being too
high risk for the procedure.”
“We now only use these mesh-covered stents at our center. I am convinced they are superior to conventional
carotid stents. The extra layer of mesh keeps the small particles of plaque that can be released during the stenting process from
entering the circulation,” Prof. Mudra added.
The full JACC paper can be purchased online here.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for
treatment of carotid artery disease by providing outstanding acute results and durable stroke free long-term outcomes.
InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are
quoted on the NYSE American under the ticker symbol NSPR.WS.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words
“intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,”
“potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions
and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be
predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such
forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i)
market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets,
(iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device
industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited
manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by
governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual
property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare
system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the
fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising
may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions,
exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of
compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the
Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at
http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of
new information, future events or otherwise.
Investor Contacts:
Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
craigs@inspiremd.com
Jeremy Feffer
LifeSci Advisors, LLC
212-915-2568
jeremy@lifesciadvisors.com
